ANI Pharmaceuticals (ANIP) reported Q3 adjusted earnings Friday of $1.34 per diluted share, up from $1.27 a year earlier.

Analysts polled by Capital IQ expected $1.09.

Net revenue for the quarter ended Sept. 30 was $148.3 million, compared with $131.8 million a year earlier.

Analysts polled by Capital IQ expected $144.4 million.

The company said it now expects fiscal 2024 adjusted earnings of $4.90 to $5.05 per diluted share, compared with its previous guidance range of $4.38 to $4.82.

Net revenue for the year is now anticipated in the range of $594 million to $602 million, compared with $540 million to $560 million anticipated previously, it added.

Analysts polled by Capital IQ expect $4.72 in normalized EPS on revenue of $590.3 million.